Cite
HARVARD Citation
Burmester, G. et al. (2016). Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Annals of the rheumatic diseases. 75 (1), pp. 68-74. [Online].